The Cooper Companies (COO)
(Delayed Data from NSDQ)
$92.69 USD
+0.08 (0.09%)
Updated Jul 30, 2024 04:00 PM ET
After-Market: $93.10 +0.41 (0.44%) 7:58 PM ET
2-Buy of 5 2
C Value F Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$92.69 USD
+0.08 (0.09%)
Updated Jul 30, 2024 04:00 PM ET
After-Market: $93.10 +0.41 (0.44%) 7:58 PM ET
2-Buy of 5 2
C Value F Growth F Momentum F VGM
Zacks News
The Cooper Companies Inc (COO), based in Pleasanton, CA, is a specialty medical device company operating on a global basis. Cooper has two business segments- CooperVision (CVI) and CooperSurgical (CSI). CooperVision manufactures and sells a wide range of contact lenses. CooperVision develops manufactures and markets a broad range of single-use, two-week and monthly contact lenses, featuring advanced materials and optics. The company’s products are primarily designed for solving vision challenges like astigmatism, presbyopia and ocular dryness. CooperSurgical sells a variety of medical devices and surgical instruments that are primarily utilized by gynecologists and obstetricians. This strategic business unit has pursued a strategy of consolidation by acquiring critical treatment niches in a fragmented market.
CONMED (CNMD) Earnings and Revenue Surpass Estimates in Q1
by Zacks Equity Research
CONMED (CNMD) witnesses growth in revenues in both its segments during Q1.
OPKO Health (OPK) Q1 Earnings Match Estimates, Revenues Top
by Zacks Equity Research
OPKO Health's (OPK) first-quarter results benefit from strength in diagnostics.
Baxter (BAX) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Baxter's (BAX) first-quarter results reflect robust performance across five of its business units.
Stryker (SYK) Earnings and Revenues Miss Estimates in Q1
by Zacks Equity Research
Stryker's (SYK) first-quarter earnings reflect strong performance across Orthopaedics and Neurotechnology and Spine segments.
Henry Schein (HSIC) to Report Q1 Earnings: What's in Store?
by Zacks Equity Research
Henry Schein's (HSIC) PPE sales from its medical business are likely to have maintained the momentum. Also, global recovery trends of its dental business are expected to aid Q1 results.
Is a Beat in the Cards for CVS Health (CVS) in Q1 Earnings?
by Zacks Equity Research
Given the increasing number of walk-in-clinical appointments and patient visits, CVS Health (CVS), which has a huge PBM client base, is expected to have seen a sequential rebound in Q1 revenues.
Zimmer Biomet (ZBH) to Report Q1 Earnings: What's in Store?
by Zacks Equity Research
Zimmer Biomet's (ZBH) first-quarter 2021 revenues are likely to have been adversely impacted due to pandemic-led lower elective procedure volumes.
Penumbra (PEN) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Growth across vascular thrombectomy and embolization products is expected to have contributed to Penumbra's (PEN) Q1 performance.
What's in Store for IDEXX Laboratories (IDXX) in Q1 Earnings?
by Zacks Equity Research
IDEXX (IDXX) first-quarter top line is expected to have benefited from strength in CAG and LPD businesses.
Thermo Fisher (TMO) to Report Q1 Earnings: WIll It Beat?
by Zacks Equity Research
Fewer hospital visits on growing new cases might have once again impacted the level of routine diagnostics testing activity for Thermo Fisher (TMO) in Q1.
New Launches in Breast Health to Aid Hologic (HOLX) Q2 Earnings
by Zacks Equity Research
Strength in Molecular Diagnostics business is likely to have continued to aid Hologic's (HOLX) performance in the second quarter of fiscal 2021.
Hologic (HOLX) to Report Q2 Earnings: What's in the Offing?
by Zacks Equity Research
Hologic (HOLX) is likely to have gained during fiscal second-quarter 2021 on the back of robust performances of its business arms despite coronavirus-led economic doldrums.
Align Technology (ALGN) to Post Q1 Earnings: What's in Store?
by Zacks Equity Research
Align Technology (ALGN) is expected to have gained from robust Invisalign aligners and iTero scanners shipment volume in Q1.
Illumina (ILMN) to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
Illumina (ILMN) is likely to have gained during the first quarter on the back of robust performance of the sequencing consumable segment.
Why You Should Hold AngioDynamics (ANGO) in Your Portfolio
by Zacks Equity Research
Investor optimism is high on AngioDynamics (ANGO) stock, courtesy of its solid prospects.
Cardinal Health (CAH), HHS Partner to Offer Pandemic Support
by Zacks Equity Research
The contract should help Cardinal Health (CAH) provide critical pandemic support in partnership with the U.S. government.
Here's Why You Should Hold on to LabCorp (LH) Stock Now
by Zacks Equity Research
Investors are optimistic about LabCorp (LH) backed by its strong diagnostic arm growth and progress in Covance business.
Here's Why You Should Hold Masimo (MASI) in Your Portfolio
by Zacks Equity Research
Investor optimism is high on Masimo (MASI) stock, courtesy of its solid prospects.
What's in Store for Edwards Lifesciences (EW) in Q1 Earnings?
by Zacks Equity Research
Continued strength in the adoption of the TruWave disposable pressure monitoring devices and INSPIRIS RESILIA aortic valve are likely to have driven Edwards Lifesciences' (EW) Q1 revenues.
Here's Why You Should Retain Quest Diagnostics (DGX) Stock
by Zacks Equity Research
Investors are optimistic about Quest Diagnostics (DGX) owing to strong demand for COVID-19 testing and well-positioned growth strategy.
What Makes The Cooper Companies (COO) a New Buy Stock
by Zacks Equity Research
The Cooper Companies (COO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Why Cooper Companies (COO) Stock Might be a Great Pick
by Zacks Equity Research
Cooper Companies (COO) has seen solid earnings estimate revision activity over the past two months, and belongs to a strong industry as well.
Here's Why You Should Retain Cooper Companies (COO) Now
by Zacks Equity Research
Investors remain optimistic about Cooper Companies (COO) backed by strong CSI and CVI product portfolios and its continued leadership in the specialty lenses market.
3 Stocks to Capitalize on Promising Dental Supplies Industry
by Trina Mukherjee
Despite the challenges thrown by the COVID-19 pandemic, teledentistry coupled with AI & Robotics should lend support to the Zacks Medical - Dental Supplies industry. MCK, WST and CAH are well-poised to gain from the prospects.
DENTSPLY SIRONA (XRAY) at a 52-Week High: What's Driving It?
by Zacks Equity Research
DENTSPLY SIRONA (XRAY) is optimistic about growth in CAD/CAM business arm along with its recent product launch and strategic buyouts.